NCT02154789

Brief Summary

Digital myxoid cysts arise from degeneration in the connective tissue of the digit joint, usually the last joint of the finger or toe, often due to underlying joint arthritis. They may connect with the joint. Pressure from the cyst can result in deformity of the digit's nail and trauma to the cyst results in leakage of the fluid, representing a potential source of entry for infection. Cysts can be tender and interfere with the digit's function. A variety of treatments are available, from simple extrusion which is rarely successful, to more destructive cryotherapy, infra-red coagulation and formal excision under local anaesthetic. These latter three approaches can result in considerable scarring. Sclerosant injection of polidocanol in one small non-randomised trial has been reported to be a well tolerated efficacious treatment with minimal scarring and long-term resolution. Following a pilot study, the investigators aim to trial this treatment to assess efficacy in a larger population.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jul 2015

Shorter than P25 for phase_4

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 15, 2014

Completed
19 days until next milestone

First Posted

Study publicly available on registry

June 3, 2014

Completed
1.1 years until next milestone

Study Start

First participant enrolled

July 27, 2015

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
Last Updated

May 30, 2024

Status Verified

May 1, 2024

Enrollment Period

2 months

First QC Date

May 15, 2014

Last Update Submit

May 28, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • cyst resolution at 6 weeks

    Is there a difference in the percentage of participants with cyst resolution at 6 weeks post treatment in those treated with polidocanol compared to those treated with the current conventional treatments of cryotherapy and infra-red coagulation?

    6 weeks

Secondary Outcomes (4)

  • cyst resolution at 12 and 52 weeks

    1 year

  • difference in scarring

    1 year

  • pain scores on a visual analogue scale

    1 year

  • procedure satisfaction on a visual analogue scale

    1 year

Study Arms (3)

polidocanol

EXPERIMENTAL
Drug: polidocanol

cryotherapy

ACTIVE COMPARATOR
Procedure: cryotherapy

infra-red coagulation

ACTIVE COMPARATOR
Procedure: infra-red coagulation

Interventions

polidocanol
infra-red coagulation
cryotherapyPROCEDURE
cryotherapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients referred to dermatology in NHS Lothian or NHS Fife who have a visible Digital Myxoid Cyst affective the dital phalynx of the toes or fingers.
  • The patient must have the ability to give informed consent

You may not qualify if:

  • History of sensitivity to polidocanol or other sclerosants
  • Age less than 18
  • Inability to give informed consent
  • Inability to report side effects experienced
  • Cyst not clearly visible
  • Cyst not fluid-filled

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Queen Margaret Hospital, Whitefield Road

Dunfermline, Fife, KY12, United Kingdom

Location

Department of Dermatology, Royal Infirmary

Edinburgh, Midlothian, EH3 9HA, United Kingdom

Location

MeSH Terms

Conditions

Ganglion Cysts

Interventions

PolidocanolCryotherapy

Condition Hierarchy (Ancestors)

CystsNeoplasmsMucinosesConnective Tissue DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Polyethylene GlycolsEthylene GlycolsGlycolsAlcoholsOrganic ChemicalsPolymersMacromolecular SubstancesBiomedical and Dental MaterialsManufactured MaterialsTechnology, Industry, and AgricultureTherapeutics

Study Officials

  • Stephen A Holme, MBChB

    University of Edinburgh

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 15, 2014

First Posted

June 3, 2014

Study Start

July 27, 2015

Primary Completion

October 1, 2015

Study Completion

October 1, 2015

Last Updated

May 30, 2024

Record last verified: 2024-05

Locations